ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2016
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).Breast (Edinburgh, Scotland) · 2020Trial
- Vascular invasion-associated gene expression is detectable in pre-surgical biopsies of stage I lung adenocarcinoma.Nature communications · 2026Article
- Pan-cancer, multi-omic correlates of survival transcending tumor lineage across 11,019 patients reveal targets and pathways.NPJ precision oncology · 2025Article
- Predicting Treatment Outcomes in Glioblastoma: A Risk Score Model for TMZ Resistance and Immune Checkpoint Inhibition.Biology · 2025Article
- Gene signatures for cancer research: A 25-year retrospective and future avenues.PLoS computational biology · 2024Article
- The role of LOXL2 in tumor progression, immune response and cellular senescence: a comprehensive analysis.Discover oncology · 2024Article
- Identification of a gene expression signature of vascular invasion and recurrence in stage I lung adenocarcinoma via bulk and spatial transcriptomics.bioRxiv : the preprint server for biology · 2024Article
- Pan-cancer investigation of psoriasis-related BUB1B gene: genetical alteration and oncogenic immunology.Scientific reports · 2023Article
- Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy.Nature communications · 2023Article
- Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker.Frontiers in genetics · 2022Article
- Improving Analysis and Annotation of Microarray Data with Protein Interactions.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Reply to: "Inconsistent prediction capability of ImmuneCells.Sig across different RNA-seq datasets".Nature communications · 2021Article
- Chemotherapy Treatment Considerations in Metastatic Breast Cancer.Journal of the advanced practitioner in oncology · 2021Review
- Weighted gene expression profiles identify diagnostic and prognostic genes for lung adenocarcinoma and squamous cell carcinoma.The Journal of international medical research · 2020Article
- Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.The pharmacogenomics journal · 2020Article
- Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings.Computational and mathematical methods in medicine · 2020Article
- A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data.BMC bioinformatics · 2019Article
- Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.JCO precision oncology · 2019Article
- Societal challenges of precision medicine: Bringing order to chaos.European journal of cancer (Oxford, England : 1990) · 2017Article
- The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches.Ecancermedicalscience · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the genomic revolution and the era of targeted therapy, prognostic and predictive gene signatures are becoming increasingly important in clinical research. They are expected to assist prognosis assessment and therapeutic decision making. Notwithstanding, an evidence-based approach is needed to bring gene signatures from the laboratory to clinical practice. In early breast cancer, multiple prognostic gene signatures are commercially available without having formally reached the highest levels of evidence-based criteria. We discuss specific concepts for developing and validating a prognostic signature and illustrate them with contemporary examples in breast cancer. When a prognostic signature has not been developed for predicting the magnitude of relative treatment benefit through an interaction effect, it may be wishful thinking to test its predictive value. We propose that new gene signatures be built specifically for predicting treatment effects for future patients and outline an approach for this using a cross-validation scheme in a standard phase III trial. Replication in an independent trial remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.